Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
P/E ratio for Orchestra BioMed Holdings, Inc. (OBIO)
P/E ratio as of 2023: -6.18
According to Orchestra BioMed Holdings, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.18. At the end of 2022 the company had a P/E ratio of -4.45.
P/E ratio history for Orchestra BioMed Holdings, Inc. from 2020 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.18 |
| 2022 | -4.45 |
| 2021 | -8.96 |
| 2020 | -12.27 |